A superior quarter in every respect. Now for the catch: there will be some dilution in Q4 due to the equity offering and I expect them to "merely" repeat the record eps of 73 cents in Q4.

However, they mentioned on the call that they are getting ready for a very busy M&A period right after reform is settled in Congress. They are debt free with a growing cash balance. This will fuel a meaningful number of acquisitions and will overcome any Medicare reimbursement cuts and (hopefully) move eps (well?) above current levels. With the current p/e, there clearly is not much growth expected.

This is going to be an exciting period for those patient enough to wait a year or so. That would include me.